#None #Maple Grove #Bora Pharmaceuticals #Corealis Pharma #Oral Solid Dose

Bora Pharmaceuticals and Corealis Pharma: A Strategic Partnership for Drug Development

In a groundbreaking move for the pharmaceutical industry, Bora Pharmaceuticals Co., Ltd. and Corealis Pharma Inc. have established a strategic alliance aimed at revolutionizing the development and manufacturing process of oral solid doses (OSD). Announced on December 9, 2025, this partnership brings together two giants in the field to create a streamlined path for drug development that addresses the complexities and inefficiencies often faced by biotech and pharmaceutical innovators.

Driven by a Shared Vision

The collaboration between Bora, a publicly listed company on the Taiwan Stock Exchange (TWSE: 6472), and Corealis, a private Contract Development Manufacturing Organization (CDMO), aims to offer end-to-end services that simplify the trajectory from drug discovery to commercial launch. As J.D. Mowery, President of Bora's CDMO division, noted, this alliance represents a blending of capabilities and cultures. By leveraging Bora's extensive commercial infrastructure alongside Corealis' expertise in formulation development and clinical-scale manufacturing, the partnership is poised to set new benchmarks in the industry.

This strategic alliance not only enhances the reliability of the development process but also offers a scalable pathway for OSD manufacturing. With the increasing complexity of drug development, the need for specialized partners has never been more critical. Bora and Corealis aim to fill this gap, ensuring that emerging biotech firms can navigate the challenging landscape of scaling their therapies effectively.

Addressing Industry Challenges

Emerging biotechnology firms often experience significant hurdles when transitioning from clinical trials to commercial production. David Leroux-Petersen, CEO of Corealis Pharma, emphasized that the collaboration with Bora is designed to tackle these hurdles head-on, providing early-stage biotech companies with a clear, rapid, and efficient route to phase III manufacturing and market launches. By integrating project management and quality systems, the partnership aims to minimize outsourcing risks, creating a seamless workflow from product discovery to commercial realization.

Quality and Expertise

Bora Pharmaceuticals brings a wealth of experience in the realm of pharmaceutical manufacturing, specializing in the development and packaging of various dosage forms, including oral solid doses, liquids, semi-solids, biologics, and sterile injectables. With state-of-the-art facilities located in both North America and Asia, Bora is dedicated to delivering high-quality drug products to over 100 markets globally.

On the other hand, Corealis Pharma is recognized for its agility and scientific acumen in the field of oral solid dosage forms. The company focuses on providing tailored formulation development and manufacturing services to biopharmaceutical firms, ensuring they meet the stringent quality demands of the industry. As a GMP-compliant organization, Corealis is trusted by a diverse client base for its commitment to excellence.

A Bright Future Ahead

The alliance between Bora Pharmaceuticals and Corealis Pharma not only signifies a pivotal moment in drug development and manufacturing but also showcases a commitment to fostering innovation within the pharmaceutical landscape. By aligning their resources and expertise, the two companies are set to create a new standard for collaboration in CDMO services, ultimately leading to faster delivery of breakthrough therapies to patients in need.

For more information on Bora Pharmaceuticals and their innovative solutions, visit BoraCDMO.com. To learn more about Corealis Pharma, check out CorealisPharma.com.

As the pharmaceutical industry continues to evolve, partnerships like this are crucial in ensuring that companies can adapt, innovate, and bring essential medications to market more effectively than ever before.